Company news

Jade Biosciences, Inc. news in 2026

Jade Biosciences, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Jade Biosciences to Participate in Upcoming Conferences

November 3, 2026

Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026

October 21, 2026

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026

September 30, 2026

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 10, 2026

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors

June 26, 2026

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

June 5, 2026

Jade Biosciences Announces Pricing of Public Offering of Common Stock

June 3, 2026

Jade Biosciences Announces Proposed Underwritten Public Offering

June 3, 2026

Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy

May 31, 2026

Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8: 00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy

May 29, 2026

Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody

May 26, 2026

Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy

May 26, 2026

Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 7, 2026

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 23, 2026

Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer

April 22, 2026

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 5, 2026

Jade Biosciences to Participate in Upcoming Conferences

February 11, 2026

Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Decks in 2026